Comparison · NCT01751802-sae
Ecopipam vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ecopipam vs Placebo: serious adverse events. Trial comparisons, record NCT01751802-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01751802-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.222 | 0.0632 | 0.547 | wilson | |
| Risk in group 2 | 0.167 | 0.0301 | 0.564 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0556 | -0.372 | 0.408 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 0.153 | 11.6 | log | |
| Odds ratio, group 1 over group 2 | 1.43 | 0.0999 | 20.4 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Ecopipam than on Placebo | 18 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ecopipam | Active substance being tested, orally once a day at bedtime~Ecopipam: Antagonist of the dopamine D1 receptor | 2 | 9 | EG000 |
| Group 2 | Placebo | Inactive substance being tested, orally once a day at bedtime~Placebo: Placebo for Ecopipam | 1 | 6 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- adverse events collected while participants were receiving ecopipam or placebo, either for 1 period (up to 6 weeks) or 2 periods (up to 12 weeks)
Source ClinicalTrials.gov
Trial
- Title
- Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
- NCT number
- NCT01751802
- Phases
- PHASE3
- Conditions
- Lesch-Nyhan Disease, Self-injurious Behavior
- Interventions
- Ecopipam, Placebo
- Lead sponsor
- Emalex Biosciences Inc.
- Results first posted
- 2015-10-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01751802?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01751802-sae